Reply:

American Journal of Neuroradiology

Download figure
Open in new tab
Download powerpoint
Fig 1.
A 16-year-old girl who underwent periodic MR imaging after gadopentetate dimeglumine (Magnevist; Bayer HealthCare Pharmaceuticals, Wayne, New Jersey) administration for operated pilocytic astrocytoma of the optic nerve during 14 years. HDN was clearly visible on both sequences (A, FSE T1WI; TE, 526 ms; TE, 12 ms. B, T1 FLAIR; TR, 1200 ms; TE, 2.46 ms; inversion recovery, 600).

Number of contrast-enhanced MRIs and amount of gadolinium administration per scan^{^a}

No.	Agent Used	Subject 1	Subject 2	Subject 3	Subject 4	Subject 5	Subject 6	Subject 7
1	Magnevist	11 mL	13 mL	13 mL	17 mL	18 mL	3.6 mL	10 mL
2	Magnevist	11 mL	13 mL	13 mL	18 mL	19 mL	4 mL	10 mL
3	Magnevist	12 mL	15 mL	15 mL	20 mL	19 mL	4 mL	11 mL
4	Magnevist	13 mL	15 mL	15 mL	20 mL	19 mL	4 mL	11 mL
5	Magnevist	13 mL	15 mL	15 mL	20 mL	19 mL	4 mL	20 mL
6	Magnevist	13 mL	15 mL	17 mL	20 mL	20 mL	4 mL
7	Magnevist	13 mL	15 mL	17 mL	20 mL	20 mL	4 mL
8	Magnevist	15 mL	15 mL	17 mL	20 mL	20 mL
9	Magnevist	15 mL	15 mL	20 mL	20 mL
10	Magnevist	15 mL	15 mL	20 mL	20 mL
11	Magnevist	20 mL	15 mL	20 mL
12	Magnevist	20 mL	15 mL
13	Omniscan	13 mL						17 mL
14	Omniscan	13 mL
15	Omniscan	13 mL

↵a T1 FLAIR was performed only in subjects 4 and 5. Although the subjects with a history of outside contrast-enhanced MRIs had been excluded, there may have been more contrast administration at outside centers because subjects had long follow-up times for underlying lesions. Therefore, the numbers illustrated in this Table should be considered as the least number of gadolinium administrations.